FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)

comunicati

FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)

26.03.2020 - 16:15

0

BALERNA, Switzerland, March 26, 2020 /PRNewswire/ -- APR Applied Pharma Research s.a. ("APR"), the Swiss pharma company leveraging drug delivery technologies to develop innovative products for niche and rare diseases, today announced that the US Food and Drug Administration (the "FDA") has granted Orphan Drug Designation for the Company's drug candidate APR-OD031 for the treatment of Phenylketonuria ("PKU").

APR-OD031 is an extended release amino acid mix engineered with a patented drug delivery technology enabling to secure physiological absorption of the delivered amino acids. This is the first mix of amino acids having a pharmacological primary mode of action designed to reduce and control Phenylalanine ("Phe") fluctuations and muscle proteolysis by reducing catabolic episodes in PKU Patients, especially Classic PKU Patients not responding to Sapropterin.

"The Orphan Drug Designation for our drug candidate APR-OD031 is a huge achievement for a small company like APR, which is focusing its efforts on the improvement of PKU standard of care. Together with the other orphan drug designation granted 6 months ago, APR is strengthening its position as a patient centric company dedicated to major unmet needs in the rare disease space," said Paolo Galfetti, CEO of APR. "As father of a PKU boy and as professional in this industry, I feel the privilege and the honor for leading a group of passionate people, all sharing the same vision to improve the quality of life of patients and families living with rare diseases. We will work closely with the FDA to complete the development and bring to the Patients this new drug as soon as possible for the benefit of the PKU community still in the need of innovative and meaningful medications."

About APR-OD031

APR-OD031 is an extended-release, Phe-free, amino acids containing formula designed to modify their release and absorption profile to mimic that of dietary proteins. APR-OD031 is engineered using the patented drug delivery Physiomimic Technology™ enabling the production of small coated granules for oral administration, processed to gradually release the amino acids in the gut. APR-OD031 is intended to reduce Phenylalanine fluctuations and muscle proteolysis in PKU patients not responding to Sapropterin. Moreover, the Physiomimic Technology™ is designed to improve patient compliance and adherence to treatments because it remarkably masks the taste and the odour of Amino Acids, with positive consequences on the typical unpleasant taste, odour, and aftertaste of traditional formulations. 

About Phenylketonuria (PKU)

PKU (Phenylketonuria) is an inherited, recessive, metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase ("PAH"). In most of the countries worldwide, PKU occurs in 1 in 10,000 to 1 in 15,000 new born babies, according to the National Human Genome Research Institute. This enzyme is required for the breakdown of Phenylalanine ("Phe"), an amino acid found in all protein-containing foods. When PAH is deficient or defective, Phe accumulates to abnormally high levels in the blood and consequently into the brain. Clinical manifestations of sustained high Phe levels include a variety of serious neurological complications, including intellectual disability and brain damage, mood disturbances, seizures and tremors, cognitive problems and executive function deficits which are clinically relevant not only in children and young people but also in adults.

About APR Applied Pharma Research s.a.

APR is a Swiss pharma company focused on development and commercialization of innovative, research-driven products designed to address unmet needs in niche and rare therapeutic areas. APR combines pharmaceutical development expertise with proprietary drug delivery technologies to develop solutions that meaningfully improve the lives of people with rare diseases. A diverse and balanced portfolio of revenue-generating products in all major markets is complemented by a robust pipeline of innovative products at different stages of development for the treatment of recessive metabolic disorders, as well as rare dermatological and ocular diseases. Products are commercialized by APR with its sales and marketing teams in selected countries of Europe and by a growing network of commercial partners. For more information, please visit: https://www.apr.ch.

Forward-looking statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "project", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

Logo - https://mma.prnewswire.com/media/899554/APR_Logo.jpg

Contact: APR Applied Pharma Research s.a.:Paolo Galfetti, Chief Executive Officerpaolo.galfetti@apr.ch +41-91-6957020

Condividi le tue opinioni su Corriere dell'Umbria

Caratteri rimanenti: 400

Più letti oggi

Mediagallery

Il sarto di Torre Maura che regala le mascherine: “Facciamo il possibile”

Il sarto di Torre Maura che regala le mascherine: “Facciamo il possibile”

(Agenzia Vista) Roma, 02 aprile 2020 Il sarto di Torre Maura che regala le mascherine: “Facciamo il possibile” A Torre Maura, Giuseppe Fassari, proprietario della sartoria a via dei Colombi, ha deciso di produrre e distribuire gratuitamente mascherine. L’idea è nata dalla sua dipendente e nel giro di pochi giorni sono diventate tantissime le persone che bussano alla sua porta per avere una ...

 
Storia di un edicolante a Roma: “Triste vedere la città vuota, vi racconto le mie giornate”

Storia di un edicolante a Roma: “Triste vedere la città vuota, vi racconto le mie giornate”

(Agenzia Vista) Roma, 02 aprile 2020 Storia di un edicolante a Roma: “Triste vedere la città vuota, vi racconto le mie giornate” Le edicole sono una delle poche attività ancora aperte nei giorni dell’emergenza coronavirus. Poche le persone che passano a comprare il giornale e ancora meno i bambini che si fermano a guardare i giochi. Ecco le parole dell’edicolante di via Appia Fonte: Agenzia Vista ...

 
La pizzeria che dona gli impasti: “Chi ha bisogno può venire a prenderli”

La pizzeria che dona gli impasti: “Chi ha bisogno può venire a prenderli”

(Agenzia Vista) Roma, 02 aprile 2020 La pizzeria che dona gli impasti: “Chi ha bisogno può venire a prenderli” I gesti di solidarietà per aiutare chi ha bisogno si moltiplicano con l’emergenza coronavirus. Simone Fortini, proprietario della pizzeria “Dietro l’Angolo” a Grottaferrata, ha deciso di donare ogni sera l’impasto della pizza. Circa 30 kg che lascia fuori dalla pizzeria, o consegna a ...

 
Coronavirus, la cultura non si ferma: i musei e i siti archeologici dell'Umbria  in due video del Mibact
coronavirus

Video La cultura non si ferma, i musei e i siti archeologici dell'Umbria 

La cultura e l'amore per il bello sopravvivono anche ai tempi del Coronavirus, anzi trasmettono valori ancor più profondi. Sono queste le sensazioni che regalano i due video dedicati al patrimonio paesaggistico e culturale dell'Umbria, pubblicati sul canale Youtube del Mibact, ministero dei Beni e delle Attività culturali e del Turismo, nell'ambito dell'iniziativa "La cultura non si ferma". Tra ...

 
Amici 2020 serale, Javier Rojas ballerino finalista su Virginia Tomarchio: "Devo combinarci qualcosa" Video

Talent

Amici 2020 serale, Javier Rojas ballerino finalista su Virginia Tomarchio: "Devo combinarci qualcosa" Video

Oggi, venerdì 3 aprile 2020, si conclude Amici 2020 serale, il talent di Maria De Filippi in onda su Canale 5. E' questo il giorno della finale. Per approfondire leggi anche: ...

03.04.2020

Coronavirus e social, Paola Barale si taglia da sola i capelli. Il video del simpatico tutorial

Paola Barale

SOCIAL

Paola Barale si taglia da sola i capelli. Il video del simpatico tutorial

Ai tempi dei social e dell'isolamento a causa del Coronavirus, ci si può inventare anche parrucchieri della propria pettinatura. Come capitato a Paola Barale. La show girl ...

03.04.2020

Stasera in tv, in prima visione Rai1 Gifted – Il dono del talento, oggi 3 marzo 2020

Televisione

Stasera in tv, in prima visione Rai1 Gifted – Il dono del talento, oggi 3 marzo 2020

Un film che è una prima visione tv quello che va in onda stasera, venerdì 3 aprile 2020. Su Rai1 Gifted – Il dono del talento. Il film drammatico  è diretto da Marc Webb e ...

03.04.2020